Mechanism of action of glutamine in portal hypertensive gastropathy in rats

Huang XiangJun; Wang YongHeng; Duan ShanShan; Li Lan; Sun GuoHui; Yang MeiYue; Leng DaYue; Zhang WenXing

doi:10.3969/j.issn.1001-5256.2018.05.029

Issue 5

May 2018

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2018 > 34(5): 1075-1079

PDF( 1698 KB)

Mechanism of action of glutamine in portal hypertensive gastropathy in rats

DOI: 10.3969/j.issn.1001-5256.2018.05.029

Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of Hunan University of Chinese Medicine

Research funding:

Received Date: 2017-11-01
Published Date: 2018-05-20

Abstract

Abstract

Objective To investigate the role and mechanism of action of glutamine in portal hypertension gastropathy ( PHG) in rats.Methods A total of 60 Sprague-Dawley rats were randomly divided into groups A ( sham-operation) , B ( sham-operation + glutamine) , C ( partial portal vein ligation) , and D ( partial portal vein ligation + glutamine) . A rat model of PHG was established by partial ligation of the main portal vein. Portal vein pressure ( PVP) , gastric injury index ( GI) , pathological integral ( PI) of the gastric mucosa, and liver morphological changes were measured after 2 weeks, and the plasma levels of alanine aminotransferase ( ALT) , aspartate aminotransferase ( AST) , albumin ( Alb) , nitric oxide ( NO) , tumor necrosis factor-α ( TNFα) , and superoxide dismutase ( SOD) were also measured. The t-test was used for comparison of continuous data between two groups, an analysis of variance was used for comparison between multiple groups, and the least significant difference t-test was used for further comparison between two groups. Results There was a significant difference in PVP between groups A, B, C, and D ( 1. 17 ± 0. 15 k Pa vs 1. 21 ± 0. 19 k Pa vs 2. 65 ± 0. 16 k Pa vs 2. 18 ± 0. 22 k Pa, F = 4. 60, P < 0. 05) , and there were also significant differences between groups C/D and groups A/B ( P < 0. 05) . There were significant differences between groups C and D in GI ( 15. 52 ± 2. 05 vs 8. 26 ± 1. 23, t = 5. 84, P < 0. 05) and PI ( 7. 56 ± 1. 53 vs 3. 15 ± 1. 42, t = 7. 45, P < 0. 05) . There were no significant differences in ALT, AST, and Alb between the four groups ( all P > 0. 05) . There were significant differences between the four groups in TNFα ( 0. 56 ± 0. 11 ng/ml vs 0. 41 ± 0. 21 ng/ml vs 1. 35 ± 0. 26 ng/ml vs 0. 68 ± 0. 21 ng/ml, F = 5. 24, P < 0. 05) , NO ( 1. 63 ± 0. 15 μmol/gpro vs 1. 41 ± 0. 12 μmol/gpro vs 5. 52 ± 1. 06 μmol/gpro vs 2. 26 ± 0. 83μmol/gpro, F = 8. 40, P < 0. 05) , and SOD ( 148. 21 ± 6. 21 U/mg vs 154. 21 ± 5. 31 U/mg vs 74. 56 ± 4. 21 U/mg vs 135. 25 ± 4. 82 U/mg, F = 14. 78, P < 0. 05) . There were significant differences in TNFα, NO, and SOD between group C and groups A/B ( all P <0. 05) , as well as between groups C and D ( all P < 0. 05) . Conclusion PHG has various pathogenic factors. Glutamine can alleviate gastric mucosal edema and hemorrhage in rats with PHG and reduce the content of NO, TNFα, and SOD. Glutamine has a good antioxidant effect and thus helps with the treatment of PHG.
- portal hypertensive gastropathy,
- glutamine,
- rats, sprague-dawley

FullText(HTML)

References(18)

References

[1]SHANG AY, YANG JM, CHEN LP, et al.Changes in gastrointestinal structure and function caused by cirrhotic portal hypertension and related clinical manifestations[J].J Clin Hepatol, 2017, 33 (2) :354-358. (in Chinese) 尚祉胤, 杨敬貌, 陈丽萍, 等.肝硬化门静脉高压导致的胃肠结构和功能改变及其临床表现[J].临床肝胆病杂志, 2017, 33 (2) :354-358.

[2]YANG Z.Current status and perspectives of surgical treatment of portal hypertension[J].J Clin Hepatol, 2016, 32 (2) :250-253. (in Chinese) 杨镇.我国门静脉高压症外科治疗的现况和展望[J].临床肝胆病杂志, 2016, 32 (2) :250-253.

[3]BANG CS, KIM HS, SUK KT, et al.Portal hypertensive gastropathy as a prognostic index in patients with liver cirrhosis[J].BMC Gastroenterol, 2016, 16 (1) :93.

[4]MASSONI F, RICCI L, PELOSI M, et al.The portal hypertensive gastropathy:a case and review of literature[J].J Clin Diagn Res, 2016, 10 (6) :hd1-hd2.

[5]SEMENOVA TS, PAL'TSEVA EM, ZHIGALOVA SB, et al.Portal hypertensive gastropathy[J].Arkh Patol, 2014, 76 (6) :64-69.

[6]MARQUES C, MAURIZ JL, SIMONETTO D, et al.Glutamine prevents gastric oxidative stress in an animal model of portal hypertension gastropathy[J].Ann Hepatol, 2011, 10 (4) :531-539.

[7]ABRALDES JG, PASARIN M, GARCIA-PAGAN JC.Animal models of portal hypertension[J].World J Gastroenterol, 2006, 12 (41) :6577-6584.

[8]VIGNERI S, TERMINI R, PIRAINO A, et al.The stomach in liver cirrhosis.Endoscopic, morphological, and clinical correlations[J].Gastroenterology, 1991, 101 (2) :472-478.

[9]GUTH PH, AURES D, PAULSEN G.Topical aspirin plus HCl gastric lesions in the rat.Cytoprotective effect of prostaglandin, cimetidine, and probanthine[J].Gastroenterology, 1979, 76 (1) :88-93.

[10]MASUDA E, KAWANO S, NAGANO K, et al.Role of endogenous endothelin in pathogenesis of ethanol-induced gastric mucosal injury in rats[J].Am J Physiol, 1993, 265 (3 Pt1) :g474-g481.

[11]SANKAR K, MOORE CM.Transjugular intrahepatic portosystemic shunts[J].JAMA, 2017, 317 (8) :880.

[12]HUNG CR, NEU SL.Acid-induced gastric damage in rats is aggravated by starvation and prevented by several nutrients[J].J Nutr, 1997, 127 (4) :630-636.

[13]TAN S, LI L, CHEN T, et al.β-Arrestin-1 protects against endoplasmic reticulum stress/p53-upregulated modulator of apoptosis-mediated apoptosis via repressing p-p65/inducible nitric oxide synthase in portal hypertensive gastropathy[J].Free Radic Biol Med, 2015, 87:69-83.

[14]LICKS F, HARTMANN RM, MARQUES C, et al.N-acetylcysteine modulates angiogenesis and vasodilation in tomach such as DNA damage in blood of portal hypertensive rats[J].World J Gastroenterol, 2015, 21 (43) :12351-12360.

[15]ABBAS Z, YAKOOB J, USMAN MW, et al.Effect of Helicobacter pylori and its virulence factors on portal hypertensive gastropathy and interleukin (IL) -8, IL-10, and tumor necrosis factor-alpha levels[J].Saudi J Gastroenterol, 2014, 20 (2) :120-127.

[16]HUANG G, DAI SL, YANG KX, et al.Research advances in portal hypertensive gastropathy[J].J Clin Hepatol, 2016, 32 (2) :358-360. (in Chinese) 黄冠, 戴树龙, 杨坤兴, 等.门静脉高压性胃病的研究进展[J].临床肝胆病杂志, 2016, 32 (2) :358-360.

[17]PRIETO I, JIMENEZ F, ALLER MA, et al.Tumor necrosis factoralpha, interleukin-1beta and nitric oxide:induction of liver megamitochondria in prehepatic portal hypertensive rats[J].World J Surg, 2005, 29 (7) :903-908.

[18]LUO Y, GE L, CHEN HB, et al.Effect of DDC on activity of SOD of bifidobacteria infantis[J].Chin J Immunol, 2016, 32 (8) :1103-1106. (in Chinese) 罗燕, 葛兰, 陈红兵, 等.DDC对婴儿双歧杆菌SOD酶活性的影响[J].中国免疫学杂志, 2016, 32 (8) :1103-1106.

Relative Articles

[1]	Du YiChao, Zhang Hao, Zhong FuRui, Cheng HuanLi, Lai Li, Qian BaoLin, Tan Peng, Xia XianMing, Fu WenGuang. Protective effect of pinocembrin in a mouse model of liver injury induced by acetaminophen[J]. Journal of Clinical Hepatology, 2020, 36(3): 608-611. doi: 10.3969/j.issn.1001-5256.2020.03.027
[3]	Li Yang, Shu DeJun, Peng CiJun, Feng ZanJie, Mei Yong, Xiong Kun. Effect of erythropoietin on the mRNA expression of apoptosis genes bcl-2 and bax in rats with fatty liver disease after hepatic ischemia-reperfusion injury[J]. Journal of Clinical Hepatology, 2019, 35(1): 157-160. doi: 10.3969/j.issn.1001-5256.2019.01.030
[4]	Lu Xin, Liu Ying, Jia Lei, Kong LingYu, Liu DianQing. Role of D-bifunctional protein in promoting the growth of hepatocellular carcinoma in rats and nude mice[J]. Journal of Clinical Hepatology, 2019, 35(7): 1532-1535. doi: 10.3969/j.issn.1001-5256.2019.07.022
[5]	Wang Hao, He Cheng, Chen Hao, Ou YangZhongMin, Liu ZhiQiang. Value of Gd-EOB-DTPA-enhanced MRI in the assessment of liver function in dogs with acute liver failure[J]. Journal of Clinical Hepatology, 2019, 35(7): 1576-1581. doi: 10.3969/j.issn.1001-5256.2019.07.030
[6]	Zhang YongChao, Bi YanZhen, Fang Xiao, Wang QuanYi, Wang QuanQuan, Tang HuiXin, Kong LingBin, Chen Yu, Duan ZhongPing, Shu ZhenFeng, Hong Feng. Protective effect of probiotics in rats with acute-on-chronic liver failure and related mechanism[J]. Journal of Clinical Hepatology, 2019, 35(7): 1570-1575. doi: 10.3969/j.issn.1001-5256.2019.07.029
[7]	Wu LinLan, Xu Bing, Wei JianWei, Zhao ZhiPing, Huang SuQin, Yang XiaoMei. Therapeutical effect of local transplantation of bone marrow mesenchymal stem cells mixed with fibrin gel on rats with liver injury[J]. Journal of Clinical Hepatology, 2018, 34(8): 1740-1744. doi: 10.3969/j.issn.1001-5256.2018.08.029
[8]	Pan Qi, Luo ChunHai, Ma WanLing, Qu YuanFei, Wang JianRu, Chen Lin. Specific magnetic resonance imaging of vascular endothelial growth factor-C targeted molecular probe and its clinical significance in a rat model of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(7): 1492-1496. doi: 10.3969/j.issn.1001-5256.2018.07.025
[9]	Liang Kai, Kong WeiZong, Chen Juan, Wang YingChun. Effect of trefoil factor 3 on intestinal mucous barrier in rats with nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2017, 33(8): 1552-1557. doi: 10.3969/j.issn.1001-5256.2017.08.029
[10]	Shi HongBo, Shi HongLin, Zhang XiangYing, Chen DeXi, Duan ZhongPing, Ren Feng. Protective effect of autophagy in mice with acute liver injury induced by D- galactosamine / lipopolysaccharide and related mechanisms[J]. Journal of Clinical Hepatology, 2017, 33(2): 329-333. doi: 10.3969/j.issn.1001-5256.2017.02.027
[11]	Li XiaoTian, Yin Yan, Guo YongZe, Zhou LiYun, You ZiXuan. Mechanism of action of 1,25(OH)_2D_3 in influencing the expression of interleukin-17 and macrophage inflammatory protein-3α and inhibiting the formation of liver fibrosis in rats[J]. Journal of Clinical Hepatology, 2016, 32(12): 2331-2336. doi: 10.3969/j.issn.1001-5256.2016.12.020
[12]	Li Dong, Lu ZhongHua, Gan JianHe. Establishment of a rat model of early-stage liver failure and Th17/Treg imbalance[J]. Journal of Clinical Hepatology, 2016, 32(5): 928-932. doi: 10.3969/j.issn.1001-5256.2016.05.025
[13]	Li XiaoPeng, Li Ming, Lei Wan, Zhang LunLi. Protective effect of magnesium isoglycyrrhizinate in rats with acute liver failure induced by D- galactosamine[J]. Journal of Clinical Hepatology, 2016, 32(3): 545-548. doi: 10.3969/j.issn.1001-5256.2016.03.032
[14]	Lai JieYing, Song SiYu, Hao LiPing, Zhang XiaoLi. Localization and therapeutic effect of bone marrow hematopoietic cell transplantation in rat model of liver fibrosis[J]. Journal of Clinical Hepatology, 2015, 31(11): 1878-1882. doi: 10.3969/j.issn.1001-5256.2015.11.026
[15]	Xu ZhongNan, Wu XiMing, Wang Pei, Zhang XiQuan, Xia ChunGuang, Wang XunQiang, Wang Yang, Zhan XiaoLe, Qu Ying, Xu MingYi, Lu LunGen. 18α glycyrrhizic acid in the treatment of acute liver injury induced by D-galactosamine in rats[J]. Journal of Clinical Hepatology, 2012, 28(1): 63-65+70.
[16]	Lu XiaoJu, Chen YongPing, Yang Tao, Shen ChunYan. Effect of baicalin of the expression of NF-κB in acute liver failure in rats[J]. Journal of Clinical Hepatology, 2011, 27(10): 1087-1092.
[17]	Wang JiPing, Leng JiYan, Dong Dong, Yan WeiQun. The protective effect of rhKD/APP on liver injured by D-galactosamine in rats[J]. Journal of Clinical Hepatology, 2007, 23(1): 24-25.
[19]	Wang JunXue, Wang GuoJun, Cai Xiong. The effects of oxymatrine on apoptosis induced by TNF-α in human liver cell line L02[J]. Journal of Clinical Hepatology, 2001, 17(4): 210-211+217.

Supplements(0)

Cited By

Cited by

Periodical cited type(6)

1.	黄成，崔海坡，谭蔚锋，芦映希，姜赫宣. 肝门阻断夹持器齿型对夹持性能的影响. 生物医学工程学进展. 2022(03): 139-143 .
2.	吴均政. 腹腔镜Pringle法联合左肝静脉阻断对左半肝切除术患者术中出血量及凝血指标的影响. 中外医学研究. 2021(26): 45-48 .
3.	石川，常华，豆松萌，李恒. Pringle联合IVC法在巨大肝血管瘤切除术中的应用效果分析. 河南外科学杂志. 2021(06): 30-33 .
4.	汪长青，吴珍宝. 不同肝血流阻断对腹腔镜肝切除术患者的影响. 西南国防医药. 2019(02): 116-118 .
5.	刘雄友，高德山，郭忠涛. 不同肝血流阻断方式对肝切除术安全性及预后的影响. 肝胆外科杂志. 2018(01): 42-46 .
6.	殷杰，徐新宝，朱日祥. 腹腔镜肝切除术治疗肝血管瘤58例临床分析. 中华肝脏外科手术学电子杂志. 2018(06): 469-472 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1904) PDF downloads(388)

Mechanism of action of glutamine in portal hypertensive gastropathy in rats

DOI: 10.3969/j.issn.1001-5256.2018.05.029